dc.contributor.author | Dahl, Helene | |
dc.contributor.author | Meyer, Klaus | |
dc.contributor.author | Sandnes, Kristina | |
dc.contributor.author | Welland, Natasha Lervaag | |
dc.contributor.author | Arnesen, Iselin | |
dc.contributor.author | Marti, Hans Peter | |
dc.contributor.author | Dierkes, Jutta | |
dc.contributor.author | Lysne, Vegard | |
dc.date.accessioned | 2023-09-19T10:59:08Z | |
dc.date.available | 2023-09-19T10:59:08Z | |
dc.date.created | 2023-06-01T13:14:39Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/11250/3090407 | |
dc.description.abstract | Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms. Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n = 53; hemodialysis n = 51, renal transplant n = 53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients’ records. Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms. Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | PLOS | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Cystatin C proteoforms in chronic kidney disease | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
dc.source.articlenumber | e0269436 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1371/journal.pone.0269436 | |
dc.identifier.cristin | 2150830 | |
dc.source.journal | PLOS ONE | en_US |
dc.identifier.citation | PLOS ONE. 2023, 18 (2), e0269436. | en_US |
dc.source.volume | 18 | en_US |
dc.source.issue | 2 | en_US |